How do you pay?

How to pay the least

Ask for the cash price

Rezdiffra

We didn’t find one.

  1. Ask your pharmacy for Rezdiffra’s cash price, and one or two other pharmacies too.
  2. Rezdiffra’s savings card works only with insurance from a job or one you bought.

Compare every option

Question
Brand nameRezdiffra
Authorized genericresmetirom
Regular genericresmetirom
What you’d pay
Cash priceAsk the pharmacy
Not soldThere isn’t one
Not soldNone found
Same as Rezdiffra?
The original
–
–

Brand nameThe maker’s card

Rezdiffra Copay Savings Card

Savings card from Madrigal Pharmaceuticals

No insuranceNeeds insuranceNo cash price listed.
Insurance · as little as $0 a month

Sign up on rezdiffra.com 

Or call 1-877-219-7770.

In the maker’s words

“Eligible commercially insured patients may pay as little as $0 a month with the Rezdiffra Copay Savings Card.”

From the maker’s offer on rezdiffra.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Rezdiffra itself, from the same company, sold without the brand name, and usually for less. For now Rezdiffra is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

We didn’t find one. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

REZDIFFRA® is a thyroid hormone receptor-beta (THR-beta) agonist indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis).

This indication is approved under accelerated approval based on improvement of MASH and fibrosis. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitations of Use

Avoid use of REZDIFFRA in patients with decompensated cirrhosis.

Source: the FDA label for Rezdiffra (Madrigal Pharmaceuticals, Inc.), July 29, 2026. Full label on DailyMed 

Good to know